

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 02/074337 A1

- (51) International Patent Classification⁷: **A61K 39/395**, 31/7088, A61P 9/00, 9/10, 17/02
- (74) Agent: **SARPI, Maurizio**; Studio Ferrario, Via Collina, 36, I-00187 Roma (IT)
- (21) International Application Number: **PCT/IT02/00153**
- (22) International Filing Date: **12 March 2002 (12.03.2002)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
MI2001A000562 **16 March 2001 (16.03.2001)** **II**
- (71) Applicant (for all designated States except US): **BIO3 RESEARCH S.R.L.** [IT/IT]; Largo Rosolino Pilo, 39/A, I-95126 Catania (IT)
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BIANCHI, Marco**, E [IT/IT]; Viale Abuzzi, 4/C, I-20068 Peschiera Borromeo (IT). **BONALDI, Tiziana** [IT/IT]; Via Griffini, 5, I-26013 Crema (IT). **SCAFFIDI, Paola** [IT/IT]; Via Asilo, 82, I-20010 Cornaredo (IT). **MUELLER, Susanne** [DE/IT]; Via Vittorio Emanuele, 15, I-20052 Monza (IT). **DEGRYSE, Bernard** [FR/FR]; Terrasse du Clos Malaga 11, F-13340 Rognac (FR).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette



WO 02/074337 A1

(54) Title: **HMGB1 PROTEIN INHIBITORS AND/OR ANTAGONISTS FOR THE TREATMENT OF VASCULAR DISEASES**

(57) Abstract: The use of HMG box-binding molecules and molecules having sequence homology with HMG box for the preparation of therapeutic agents for the treatment of vascular diseases is described

HMGB1 PROTEIN INHIBITORS AND/OR ANTAGONISTS FOR THE
TREATMENT OF VASCULAR DISEASES.

The present invention concerns the field of molecular biology and more particularly HMGB1 protein inhibitors and HMGB1 antagonists to be used for the treatment of vascular diseases, including those due to angioplasty.

HMGB1 protein (known, before 2001, as HMG; Bustin, 2001, Trends Biochem. Sci., 26, 152-153) is the archetypal protein of the HMG-box family, which is characterised by the presence of DNA binding domains, called HMG boxes. HMG1 is a small 25-kD protein, of 215 amino acids, with a highly conserved sequence among mammals. The HMGB1 molecule is organised into three domains: two DNA binding domains, HMG Box A and Box B, which are followed by an acidic COOH terminus composed of 30 glutamic and aspartic residues. The two HMG boxes, box A and box B, are 80 amino acid segments (29% identical, 65% similar), having an L-shaped tridimensional structure (Hardman et al., 1995, Biochemistry, 34:16596-16607; Read et al., 1993, Nucleic Acids Res., 21:3427-3436; Weir et al., 1993, EMBO J., 12:1311-1319).

HMGB1 has originally been identified as a ubiquitously expressed, abundant nuclear protein. It is present in more than 1 million copies per single nucleus and binds double stranded DNA without sequence specificity. Instead, HMGB1 binds with high affinity to specific DNA

structures like kinked or bent DNA and four-way junctions. However, HMGB1 can be recruited to double stranded DNA by interaction with several different DNA-binding proteins. When bound to double stranded DNA, it induces structure distortion, allowing the formation of nucleoprotein complexes where several DNA-binding proteins can contact each other while bound to their respective DNA cognate sites (Müller et al., 2001, EMBO J., 16: 4337-4340 and other reference cited herewithin). The phenotype of Hmgb1 ^{-/-} mice is in agreement with this model (Calogero et al., 1999, Nat. Genet., 22:276-280).

Recently, an additional role for HMGB1 outside the cell nucleus has come into focus: HMGB1 works as late mediator of endotoxin-induced lethality as well as acute lung inflammation in mice; as well the elevated serum level of HMGB1 in septic patients is a prognosis marker (international patent application No. WO 00/47104). HMGB1 can be secreted by macrophages and pituicytes in culture in response to cytokines and bacterial endotoxin (Abraham et al., 2000, J. Immunol., 165: 2950-2954; Wang et al., 1999, Surgery (St. Luis), 126:389-392; Wang et al., 1999, Science, 285:248-251). The release of HMGB1 from murine erythroleukemia cells is correlated with cell differentiation and the protein can be found in a plasma membrane-associated form in these cells (Passalacqua et al., 1997, FEBS Lett., 400:275-279; Sparatore et al., 1996, Biochem. J., 320:253-256). A protein called amphoterin, identical in sequence to HMGB1, has been described in the brain,

where it is found in the nucleus and cytoplasm of neuronal cells as well as in the extracellular space. If exogenously added, HMGB1 mediates outgrowth of neurites, and laminin-dependent migration of neuroblastoma and glioma cells is inhibited by antibodies against HMGB1 (Fages et al., 2000, J. Cell Sci., 113:611-620; Merenmies et al., 1991, J. Biol. Chem., 266:16722-16729; Parkkinen et al., 1993, J. Biol. Chem., 268:19726:19738; Rauvala et al., 1988, J. Cell Biol., 107:2293-2305). Interactions between HMGB1 and the plasminogen activation system, in particular t-PA (tissue-type plasminogen activator), results in enhanced plasmin formation (Parkkinen and Rauvala, 1991, J. Biol. Chem., 266: 16730-16735). Degradation of extracellular matrix proteins is an important step in the cell migration process, and HMGB1-promoted increase of extracellular protease activity might enable the cells to migrate.

HMGB1 has been identified as one of the ligands binding to the RAGE receptor (Receptor for advanced glycation endproducts) (Hori et al., 1995, J. Biol. Chem., 270: 25752-25761). RAGE is a multiligand receptor of the immunoglobulin superfamily and is expressed in many cell types, including endothelial cells, smooth muscle cells, mononuclear phagocytes, and neurons (Brett et al., 1993, Am. J. Pathol., 143: 1699-1712; Neeper et al., 1992, J. Biol. Chem., 267: 14998-15004). It is implicated in several different pathological processes, such as diabetes, amyloidoses, and atherosclerosis (Schmidt et al., 1999, Circ. Res.,

84: 489-497). Interaction of HMGB1 and RAGE induces neurite outgrowth, and the two proteins colocalize at the leading edge of advancing neurites during embryonic development (Huttunen et al., 1999, J. Biol. Chem.,
5 274:19919-19924). The block of tumour growth and metastasis is observed preventing the interactions between HMGB1 and RAGE; moreover, inhibition of this interaction suppresses activation of mitogen-activated protein (MAP) kinases and the expression of matrix
10 metalloproteinases, molecules importantly linked to tumour proliferation and invasion (Taguchi et al., 2000, Nature, 405: 354-360).

The inventors of the present invention, demonstrated that HMGB1 has a potent biological effect
15 on smooth muscle cells (SMC), one of the cell types where RAGE is expressed on the surface. Vascular SMC cells are the most predominant cells of the larger blood vessels; they are located in the tunica media where are embedded in the extracellular matrix. In
20 intact vessels, SMC cells are in a contractile state and show a phenotype characterised by the absence of cell division and migration responsible for vessel wall rigidity and elasticity maintenance and blood pressure control.

25 When the endothelium is damaged, either after mechanical or inflammatory injuries, SMC cells switch to a synthetic phenotype and undergo cell division and cell migration. The migration of SMC cells from the tunica media to the tunica intima, resulting in intimal
30 thickening, plays an important role in the

pathophysiology of many vascular disorders, such as atherosclerosis and restenosis after coronary angioplasty. In the synthetic state, SMC cells also produce higher amounts of extracellular proteinases, growth factors, and cytokines and secrete a fibrous extracellular matrix. After vessel wall injury, the release of several growth factors and/or chemoattractants either by circulating monocytes, macrophages and platelets, or by damaged endothelial cells can induce SMC cells switch from the contractile to the synthetic phenotypes and it can direct the migration of SMC cells towards the vessel intima. Among these factors, bFGF appears to be one of the most important, but however, SMC cells can also start migration in response to angiogenic stimuli (Schwartz, 1997, J. Clin. Invest., 99:2814-2816; Van Leeuwen, 1996, Fibrinolysis, 10:59-74).

Trying to define the effect and the mechanism by which HMGB1 induces RSMC cell migration, the inventors demonstrated that HMGB1 is a strong chemoattractant and it induces their cell shape changes, and cytoskeleton reorganisation. These events are inhibited by addition of an anti-RAGE antibody and by pertussis toxin, underlining that both RAGE and a Gi/o protein might be involved in the pathway. Furthermore, the evidence that HMGB1 promotes the translocation of phosphorylated ERK 1 and 2 proteins into the nucleus, indicates the involvement of the MAP kinase pathway. Then, it has been demonstrated that HMGB1 is released by damage or

necrosis of a variety of cell types, including endothelial cells.

Therefore, HMGB1 has all the hallmarks of a molecule that can promote atherosclerosis and restenosis after
5 vascular damage.

The inventors also demonstrated that HMGB1 fragments, corresponding to HMG boxes, are more efficacious than the entire full-length molecule and even HMG box domains of other proteins of the HMG-box
10 family can induce the same effects.

Consequently, every kind of molecules able to block the interaction between HMGB1 and its RAGE receptor (i.e. all the molecules belonging to the inhibitors class: antibodies or antibodies fragments, fourway DNA;
15 and all the molecules belonging to the HMG box-antagonist class: HMGB1 fragments molecules containing the HMG box domain) can efficiently be used for the production of pharmacological preparation in order to avoid, retard or inhibit atherosclerosis and restenosis
20 after vascular epithelium damage even due to angioplasty.

HMGB1-binding molecules or HMGB1 inhibitors can be injected or released by instruments used for angioplastic surgery, or said molecules can be bound to
25 the instruments' surface.

Object of the present invention is the use of molecules able to block the interaction between HMGB1 and RAGE for the preparation of therapeutic agents for the treatment of vascular diseases.

In a preferred embodiment of the invention said molecules are released by catheters, surgical instruments or stents for angioplasty, during or after said operation.

- 5 Further features and advantages of the invention will be more readily apparent from the following detailed description with reference to the accompanying drawings.

In the drawings:

- 10 Figure 1 shows HMGB1 chemotactic activity on RSMC in chemotaxis assays performed using modified Boyden chambers. The value of 100% corresponds to the number of cells migrating in the absence of any stimulator (random cell migration). The data represent the mean \pm
15 SD (n=3). Figure 1-A shows concentration-dependent migratory response of RSMC to HMGB1 purified from calf thymus. Figure 1-B shows the comparison of the chemotactic effect of HMGB1 proteins, either purified from calf thymus or expressed in yeast, with those of
20 chemoattractants fMLP and bFGF. Figure 1-C shows the effect of anti-HMGB1 antibodies on fMLP- and HMGB1-induced migration. The asterisk (*) indicates treatments where the migratory response was statistically different from the control beyond the
25 p=0.0001 limit in Student's test. Figure 1-D shows the concentration-dependent migratory response of RSMC to HMGB1 expressed in yeast (*Pichia pastoris*).

- Figure 2 shows the effect of HMGB1 on RSMC morphology and cytoskeleton organization. Figure 2-A
30 shows the effect of HMGB1 purified from calf thymus or

expressed in yeast or in *E. coli* on subconfluent cultures of RSMC. Actin filaments were visualised using TRIC-phalloidin. Figure 2-B shows how anti-HMGB1 rabbit antibodies inhibit HMGB1-stimulated cytoskeleton reorganization. Resting cells (state 1) exhibit numerous stress fibers. Nonresting cells (state 2) show a reorganization of actin cytoskeleton.

Figure 3 shows the chemotactic response of RSMC to the HMG box domains of HMGB1. Figure 3-A shows the concentration-dependent response to Box A e Box B, both expressed in *E. coli*. Random cell migration is referred to as 100% migration. The data represent the mean \pm SD ($n=3$). The statistical significance of the result is $p<0.0001$ in a ANOVA model, for both Box A and Box B. Figure 3-B shows the effects of full-length HMGB1 expressed in *E. coli*, Box A+B, Box A or Box B on actin cytoskeleton organization. Actin filaments were visualized using TRIC-phalloidin.

Figure 4 shows the effects of HMGB1 and its HMG boxes on RSMC migration into a wound. The value of 100% corresponds to the number of cells migrating in the absence of any stimulator (basal migration). The data represent the mean \pm SD ($n=5$). Statistical significance is $0.05<p<0.01$ for the treatment with bFGF and full-length bacteria-made HMGB1, $0.01<p<0.001$ for the treatment with Box A and Box B and $0.001<p<0.0001$ for the treatment with calf thymus HMGB1.

Figure 5 shows how HMGB1 binds to the surface of RSMC and stimulates cell motility through RAGE. Figure 5-A shows that large amounts of HMGB1 bind to the

surface of RMSC. In figure 5-B RSMC expressing RAGE are shown. Figure 5-C shows how anti-RAGE antibody inhibits HMGB1-induced RSMC migration. Statistical significance is $0.001 < p < 0.0001$ for treatment with HMGB1 and HMGB1 plus unspecific antibody.

Figure 6 shows how pertussis toxin (PT) inhibits HMGB1-induced RSMC migration and actin cytoskeleton reorganization. In figure 6-A chemotaxis assays performed using modified Boyden chambers are shown. The value of 100% corresponds to basal cell migration in the absence of any stimulator; the data represent the mean \pm SD. Figure 6-B shows evident cytoskeleton reorganization, actin filaments were visualised using conjugated TRITC-phalloidin.

Figure 7 demonstrates that the MAP kinase pathway is involved in HMGB1 signaling. Cells are stained with specific antibody against phosphorylated ERK1/2 and DAPI, and a separate sample of cells is stained with TRITC-phalloidin to visualize the reorganization of the cytoskeleton.

Figure 8 shows that HMGB1 is released by necrotic and damaged cells. Figure 8-A shows the results of Western-blot analysis of proteins released by necrotic or permeabilized HeLa; HMGB1 presence is evident in line 1 and line 3. Figure 8-B shows the results of immunofluorescence assays performed on necrotic and living HeLa.

Figure 9 shows that HMGB1 is present in the nuclei of endothelial cells, but not in those of vascular SMC. In figure 9-A and in figure 9-B it is shown that HMGB1

is present in the nuclei of endothelial cells but it is not detectable in the nuclei of vascular smooth muscle cell of a section of human pancreatic artery stained with anti-HMGB1 antibody and counterstained with
5 ematoxylin, at low (A) and high (B) magnification. The red frames indicate the location of the area shown in figure B and the arrows point to the nuclei of SMC. In figure 9-C Western blot analysis shows expression level of HMGB1 in RSMC in comparison to HeLa cells.

10 Figure 10 shows the chemotactic effect of HMGB1 on mouse embryonic fibroblasts in chemotaxis assays performed using modified Boyden chambers, in the presence or in the absence of anti-RAGE antibodies (1000 ng/ml). The value of 100% corresponds to the
15 number of cells migrating in the absence of any stimulator (random cell migration). The data represent the mean \pm SD (n=3).

Expression and purification of HMGB1 and derivates

20 In the first step, it has been necessary to express and purify HMGB1 and derivates.

Expression of full-length HMGB1 was performed in E. Coli transformed with pT7-7-rHMGB1cm plasmid (kind gift of Prof. J.O. Thomas, Cambridge University) and
25 purification was performed following a well-known protocol (Müller et al., 2001, Biochemistry, 40: 10254-10261).

Expression and purification of full-length HMGB1 in yeast *Pichia Pastoris* were performed following a well-

known protocol (Mistry et al., 1997, Biotechniques, 22:718-729).

The well-known plasmids pRNHMG1/M1-V176, pT7HMG1bA and pT7HMG1bB were used for the expression and
5 purification of BoxA + BoxB, BoxA and BoxB respectively following well-known procedures of purification of the single and double boxes (Bianchi et al., 1992, EMBO J., 11: 1055-1063).

To demonstrate chemotactic effect of HMGB1, three
10 independent cell migration assays were performed: chemotaxis assay, chemokinesis assay and in vitro wounding assay. The functional relationship between HMGB1-induced cell migration and morphological changes (i.e. actin fibers reorganization, cell elongation and
15 cell's shape polarization) of nonresting cells was investigated.

Chemotaxis assay

Chemotaxis assays were performed using well-known
20 protocols (Degryse et al., 1999, Blood, 94:649-662). Modified Boyden chambers were used with filters having 0.5 μ m pore size (Corning, Acton, MA) and treated with collagen I (100 μ g/ml in 0.5 M acetic acid) e fibronectin (10 μ g/ml) (Roche). RSMC cells (kind gift
25 of Dr. Marco Bertulli, Bayer Research Laboratories, Milan) were cultured in DMEM serum-free and a sample of 20.000-40.000 cells was added to the upper well of Boyden chamber. The molecules to be tested were diluted in the same serum-free medium and added to the lower
30 well.

Different HMGB1 preparations were used: HMGB1 purified from calf thymus (kind gift of J. Bernués, C.S.I.C., Barcelona, Spain), E. coli expressed recombinant-HMGB1, and a lightly modified HMGB1 form
5 (containing EAEAYVEF aminoacids bound to the N-terminus) produced in yeast Pichia pastoris (Mistry et al., 1997, Biotechniques, 22:718-729).

If necessary, the polyclonal rabbit anti-HMGB1 (Pharmingen BD, Torrey Pines, CA), the pertussis toxin
10 (PT) from Bordetella pertussis (kind gift of Dr. M.G. Pizza, I.R.I.S., Siena) or the inhibitors were added in both wells.

Overnight cell migration was allowed at 37°C, then cells remaining on the upper surface of filters were
15 scraped off and filters were fixed in methanol and stained in a solution of 10% crystal violet in 20% methanol. All experiments were performed at least twice in triplicate.

Results, as shown in figure 1-A, 1-B, 1-C, 1-D, are the
20 mean \pm SD of the number of cells counted in 10 high power fields per filter and expressed as fold over control. To random cell migration (i.e., migration in the absence of chemoattractant) was given the arbitrary value of 100%.

25 Statistical analysis was performed using Student's t test for pairwise comparisons of treatments, or an ANOVA model for the evaluation of treatments with increasing doses of a reagent.

HMGB1 from calf thymus stimulates migration of RSMC
30 in a concentration-dependent manner, starting at doses

as low as 0.1 ng/ml and with a 2.5-fold maximal response at 100 ng/ml (Figure 1-A). The effect of HMGB1 is comparable in amplitude to the effects of the well-characterised attractants fMLP and bFGF (Figure 1-B).

5 Polyclonal antibodies against HMGB1, but not nonspecific control antibodies, totally block the migratory response (Figure 1C), showing that this is specifically due to HMGB1. These antibodies fail to

10 alter the effect of the chemoattractant peptide fMLP used as positive control. Similar results are obtained with recombinant HMGB1 produced in yeast *P. pastoris* (Figure 1-D).

Immunofluorescence assay

15 Samples of 15,000-20,000 RSMC, 20-40% confluence, were seeded on glass coverslips in 2 cm² wells and cultured for 24 hours in DMEM plus 10% FCS, washed with PBS, and cultured for another 24 hours in DMEM without FCS. RSMC were stimulated with HMGB1 100 ng/ml for

20 increasing time intervals, from 5 to 120 minutes at 37°C. After stimulation, RSMC were fixed for 20 minutes at room temperature with a solution of 3% paraformaldehyde, 2% sucrose in PBS, pH 7.5, followed by three washes with PBS-BSA 0.2%. Cells were

25 permeabilized with 20 mM Hepes pH 7.4, 300 mM saccharose, 50 mM NaCl, 3 mM MgCl₂, 0.5% (v/v) Triton X-100 for 3 minutes at 4°C, and washed again three times with PBS-BSA 0.2%. Then, RSMC were incubated with PBS-BSA 2% for 15 minutes at 37°C, with primary

30 antibodies for 30 minutes at 37°C, washed three times

with PBS-BSA 0.2%, and further incubated with PBS-BSA 2% for 15 minutes. At the end, cells were stained with secondary antibodies and/or phalloidin conjugated with rodamin for visualization of filamentous actin; in some cases, DAPI (4',6-diamidino-2-phenylindole, Roche) was used to label the nucleus.

After all the subsequent incubation, coverslips were washed three times with PBS-BSA 0.2%, twice with distilled water, mounted with 20% Mowiol in PBS and analysed on a Axiophot microscope (Carl Zeiss). Fluorescence photographs were taken either on T-Max 400 or EPH P1600X film (Eastman Kodak) using Zeiss 40 and 100 neofluar lenses.

Low magnification pictures, in figure 2-A, show that stress fibers content, cell shape and size, and cytoskeleton organization change within 30 minutes, but reverse after 120 minutes. Higher magnification pictures (figure 2-B) show that before stimulation are well-visible numerous stress fibers and the cell shape is a nonpolarized. Within 15-30 minutes, a complete change of morphology and cytoskeleton organization occurs: RSMC show an elongated, polarized morphology that reflected the spatial rearrangement of the actin cytoskeleton. The effects of HMGB1 slowly decrease: After 1-2 hours, the stress fiber content increases back to the initial level and cell morphology returns similar to that of unstimulated control cells.

In certain experiments cells were overnight pretreated with antibodies or PT or inhibitors. As shown in figure 2-B, antibodies against HMGB1 totally

inhibit the cytoskeletal reorganization and the morphological change of RSMC induced by HMGB1. Control antibodies are not able to inhibit HMG1 effects.

Finally, to determine whether the observed effects of HMGB1 on RSMC actually reflect a dynamic transition from resting to motile states, the proportion of cells in each different state was quantified. Low magnification pictures were taken and the cells were classified in two states:

- 10 - state 1, where cells show the appearance typical of unstimulated cells characterized by a high number of stress fibers and a nonpolarized cell shape;
- state 2, where RSMC exhibiting a low stress fibers content, membrane ruffling, actin semi-rings, or
15 an elongated shape.

It is clearly shown in figure 2-C that in unstimulated cultures 60% of the cells are in state 1 and 40% in state 2; within 5 minutes after stimulation, the proportion of cells in state 2 increases to 60%,
20 and rose to 80% after 15-30 minutes. One hour after stimulation with HMGB1, these proportions reverse back to the values of unstimulated cultures, with 60% of RSMC in state 1 and 40% in state 2. These data demonstrate that HMGB1 effects are transient and
25 represent the change from a resting to a migrating state, these data confirm chemotaxis results: HMGB1 is a chemoattractant for RSMC.

In vitro wounding assay

Confluent cultures of RSMC, grown on glass coverslips in 2-cm² wells, were washed once with PBS and FCS-starved for 24 hours in serum-free DMEM. Then to simulate the wound, a single line was made with the tip of a pipette in the central region of the monolayers. The so treated monolayers, were washed once with PBS and are allowed to recover for 48 hours in serum-free medium supplemented or not with HMGB1 (100ng/ml). Then cells were fixed and stained with TRITC-phalloidin. Quantification of the migration was made by taking photographs at lower magnification and by counting the number of cells that had migrated into the cell-free space. The data represent the mean \pm SD and the value 100% corresponds to the number of cells migrating in the absence of any stimulator (basal migration).

As shown in figure 4, HMGB1 stimulation increases the number of migrating cells by 5-2-fold. Box A and Box B (10 ng/ml) were also tested and both stimulate cell migration 1.8-fold. Finally, the comparison with bFGF (50 ng/ml) underlines that the above mentioned molecules are more effective. It is possible to assume that wound healing is based on the same signaling pathway of chemotaxis and chemokinesis.

25 Signaling pathway

Afterwards, signaling pathway has been detected.

To act as a migratory signal, HMGB1 must arrive to the membrane of responsive cells and bind to a receptor. To test whether HMGB1 binds to the surface of RSMC, one million cells were trypsinized and incubated

for 20 minutes at 4°C in PBS containing 800 ng of the Box A+B peptide and 5 µg BSA. The BoxA+BoxB polypeptide is slightly smaller than the endogenous full-length HMGB1 and can thus be distinguished easily on SDS-PAGE
5 gels. Then, cells were pelleted and the supernatant was saved; after two washes in 500 µl cold PBS, cells were resuspended in SDS-PAGE sample buffer, heated for 5 minutes at 100°C and loaded on 12% tricine-SDS gel (line P), adjacent to 20 µl of supernatant (line S).
10 Then, the gel was blotted to a Immobilon filter, which was stained with India ink.

In figure 5-A a SDS-PAGE gel is shown, from which the amount of Box A+B recovered in the cell pellet and in the supernatant can be calculated, and it can be
15 estimated that more than 500 000 Box A+B molecules bind to a single RSMC. This result demonstrates that extracellular HMGB1 can bind to RSMC, but most likely does not reflect the actual receptor number. Indeed, HMGB1 has already been shown to bind to heparin and
20 proteoglycans (Bianchi, 1988, EMBO J., 7: 843-849; Nair and Jungalwala, 1997, J. Neurochem., 68: 1286-1297; Salmivirta et al., 1992, Exp. Cell Res., 200: 444-451); thus, HMGB1 might also be associated with the extracellular matrix produced by RSMC, as already
25 demonstrated by the inventors in HeLa, where only small amounts of HMGB1 bind to cells because these cells produce little extracellular matrix.

HMGB1 has been reported to bind to RAGE that is expressed by a vast range of cell types. To demonstrate
30 that RAGE is present on RSMC membrane, one million RSMC

were lysed in a plate containing SDS-PAGE sample buffer (50 mM Tris pH 6.8, 2% 2-mercaptoethanol, 4% SDS, 12% glycerol, 0.05% bromophenol blue), denaturated for 5 minutes at 100°C and separated on 12 % acrylamide.

5 Separated proteins were blotted on Immobilon (Millipore) membrane using a tankblot system 25 mM Tris pH 7.5, 0.192 M glycine, 20% methanol. The blot was blocked for one hour at room temperature in 5% skim milk/TBST (20 mM Tris, pH 7.5, 137 mM NaCl, 0.1% Tween

10 20), three time washed in TBST, and incubated with anti-HMGB1 antibody in TBST-0.01% BSA. Incubation with secondary antibody was conducted after washing with TBST-0.01% BSA. Proteins were detected with ECL system (Amersham). The presence of RAGE was detected using

15 anti-RAGE antibody (kind gift of Dr. A.M. Schmidt, Columbia University, NY). Results shown in figure 5-B demonstrate that RAGE is present on RSMC. Furthermore, HMGB1-induced chemotaxis is not only inhibited by anti-HMGB1 antibodies but also by anti-RAGE antibodies, as

20 shown in figure 5-C. Anti-RAGE antibodies block cytoskeletal reorganization and morphological changes of RSMC in response to HMGB1 migratory signal; irrelevant antibodies are not able to block cytoskeleton reorganization

25 These data indicate that the RAGE receptor is required for the HMGB1-induced responses of RSMC.

Knowing that many chemoattractants act via membrane receptors associated to heterotrimeric GTP binding proteins (G proteins), whether G proteins could be

30 implicated in HMGB1 signaling was tested. The pertussis

toxin (PT) was used because it inhibits a specific subclass of G proteins, the Gi/o proteins, and it reveals their involvement in the signaling pathway (Baggiolini et al., 1994, Adv. Immunol., 55:97-179; 5 Haribabu et al., 1999, J. Biol. Chem., 274:37087-37092). mPT, an inactive mutant of PT, was used as a control. RSMC were pre-treated with PT or with mPT (50 ng/ml) for 6 hours, thus stimulated with HMGB1 (100 ng/ml), BoxA or BoxB (10 ng/ml) for 30 minutes. 10 Chemotaxis assays were performed as previously described. The data represent the mean \pm SD and the value of 100% corresponds to basal migration in the absence of any stimulator. In figure 6-A the inhibitory effect of PT on HMGB1-induced chemotaxis is shown. 15 These data suggest the involvement of Gi/o proteins in the signaling pathway controlled by HMGB1. In figure 6-B the cytoskeleton reorganization is shown, actin filaments were visualised as previously described. Afterwards, whether the HMGB1-induced signaling 20 involves the MAP kinase pathway, was investigated; in fact, it is known that these proteins are activated by RAGE, and they have a direct role in the regulation of the intracellular motility machinery. RSMC were pre-treated with PD98059 (50 mM) for one hour or were not 25 pre-treated, stimulated for 30 minutes with HMGB1 from calf thymus (100 ng/ml) and stained with specific antibodies against phosphorylated ERK1/2 (New England Biolabs, Beverly, MA) and DAPI. A separate sample of cells was stained with TRITC-phalloidin to visualize 30 the reorganization of cytoskeleton. In figure 7 is

shown how, within 30 minutes, HMGB1 stimulation induces the activation of ERK1/2 proteins in RSMC and induces their nuclear translocation; in contrast, phosphorylated ERK proteins are hardly detectable and located in the cytoplasm, in unstimulated RSMC. Moreover, PD98059, the selective inhibitor of MEK, the upstream regulator of ERK, inhibits HMGB1-induced ERK phosphorylation and nuclear translocation, as well as RSMC migration and cytoskeleton reorganization. Consequently, these data show that the MAP kinase pathway plays an essential role in HMGB1-induced cell migration.

Induction of cell damage

Considering the state of the art, has been detected whether damaged cells or cells undergoing necrosis could release HMGB1 in the extracellular medium.

HeLa cells and HUVEC were induced to undergo necrosis by treatment with 5 μ M ionomycin (Sigma) and 20 μ M CCCP, or mM deoxyglucose and 10 mM sodium azide. After 16 hours at a 37°C, the number of cells undergoing necrosis was scored morphologically, and when it approached 50% the supernatant was collected.

For Western blot analysis, the medium from treated and untreated cells was collected and concentrated 50-fold using Amicon Ultrafree-MC filters; the cells were dissolved in the SDS-PAGE sample buffer.

For immunofluorescence analysis, the cells were fixed with 4% PFA, incubated with an anti-HMGB1 antibody, and stained with secondary antibody and DAPI.

The permeabilization of cells was performed with using 0.1% NP-40 in PBS.

In figure 8-A, Western-blot analysis of protein in supernatants (S) and cell pellets (P) is represented, HMGB1 was recovered in the supernatant of both necrotic cells and damaged cells. In figure 8-B immunofluorescence assays performed on single living and necrotic HeLa is shown, HMGB1 is not associated to the remnants of necrotic cells.

In figure 9 the results of immunohistochemistry assays are shown, these data confirm that HMGB1 is contained in the nuclei of endothelial cells that line human arteries but not in the nuclei of RSMC (figure 9-A low magnification; figure 9-B high magnification), in fact, most nuclei of smooth muscle cells contain undetectable amounts of HMGB1 (frame in Figure 9-B). In figure 9-C, Western-blot analysis shows the expression level of HMGB1 in RSMC in comparison to HeLa cells, and it demonstrates that in vitro cultures of RSMC contain low amounts of HMGB1 in comparison to HeLa cells.

Altogether, these data suggest that the HMGB1 molecules that signal to vascular smooth muscle cells may originate simply by necrosis or mechanical damages of nearby cells.

In conclusion, the above mentioned experimental data, foundations of the present invention, demonstrate that nuclear HMGB1 protein is a strong mediator of vascular remodeling occurring after mechanical damage and/or inflammation and can be passively released by damaged or necrotic cells.

In particular these data suggest what follows:

HMGB1 ACT AS A CHEMOATTRACTANT

HMGB1 is a potent chemoattractant as bFGF or fMLP
5 in chemotaxis assays and wounding assays, and promotes
changes of cell shape and of cytoskeleton organization
similar to those observed with pro-urokinase; these
effects are specifically due to HMGB1 and not to
potential contaminants. In addition, antibodies
10 directed against HMGB1 inhibit its effects on cell
migration, whereas nonspecific control antibodies are
unable to do so.

BINDING TO RAGE INITIATES THE HMGB1 SIGNALING PATHWAY IN 15 RSMC

The above reported experiments show that RAGE is
expressed in RSMC, and anti-RAGE antibodies inhibit the
effect of HMGB1 on RSMC.

It was confirmed that MAP kinases are involved in
20 HMGB1-induced cell migration of RSMC, since ERK1/2 are
phosphorylated and translocated to the cell nucleus
upon HMGB1 stimulation, and the MEK inhibitor PD98059
is able to block HMGB1-induced cell migration. Data
also indicate that a Gi/o protein is involved in the
25 process which is activated by HMGB1, since HMGB1-
induced cell migration can be blocked by Bordetella
pertussis toxin. G protein are usually associated to
seven-transmembrane-elix receptors (7TM), but so far no
direct association between RAGE and G protein has been
30 described. Up to now, it is unknown if HMGB1 need to

bind a 7TM receptor/G protein receptor in addition to RAGE, or if a G protein is involved downstream to RAGE, or in a feedback mechanism.

5 HMGB1 PARACRINE FUNCTION

HMGB1 is released in a unregulated manner, which means upon stimulation with cytokines or lipopolysaccharide, when cells are mechanically damaged or undergo necrosis. Thus, HMGB1 can signal the damage or
10 destruction of an individual cell to the neighbouring cell in a paracrine manner. The cells that respond to extracellular HMGB1 appear to contain very little HMGB1 themselves, and almost none in the nucleus. RSMC contain very little HMGB1 compared with HeLa cells or
15 endothelial cells, and what little HMGB1 they contain is mainly located in the cytoplasm. Migrating RSMC tend to concentrate HMGB1 on their surface at the leading edge of the cell. It can be supposed that HMGB1-responsive cells could contain little HMGB1 to reduce
20 the chance of inappropriate responses to their own HMGB1. Concentration of HMGB1 at the leading edge of migrating cells might evoke HMGB1-induced responses in neighbouring cells: relocation of molecules involved in cell migration, such as integrins, the urokinase
25 receptor, or c-Src, is a feature of motile RSMC. Migration also involves the activation of extracellular proteases, and the interaction between HMGB1 and the plasminogen activation system might facilitate cell migration within the extracellular matrix.

30

ROLE OF HMGB1 IN VASCULOPATHIES

The responsiveness of smooth muscle cells to HMGB1, the observation that endothelial cells contain high amounts of HMGB1 while vascular SMC contain little, and
5 the release of HMGB1 from cells undergoing mechanical damage, all the above results point to a possible role of HMGB1 during the tissue remodeling occurring in atherosclerosis and restenosis.

The above specified experimental results permitted
10 to identify the molecules, object of the invention, able to inhibit the interaction between HMGB1 and RAGE receptor; these molecules are classified, considering their structural and functional characteristics, as follows:

15 1. HMGB1 antagonists: HMGB1 fragments, HMG box analogues, which can be more effective than the entire full-length molecule, and proteins containing HMG box domains, the last two are both able to bind to RAGE receptor.

20 2. HMGB1 inhibitors: molecules, as antibodies or antibody fragments and four-way DNA, which bind to HMG box domain and avoid HMGB1 binding to RAGE.

These molecules are advantageously used for pharmacological preparation which prevent, retard or
25 minimise atherosclerosis and/or restenosis after vascular epithelium damages, including those events that occur after angioplasty.

Furthermore, the inventors of the present invention demonstrated that HMGB1 has a strong biological effect
30 on mouse embryonic fibroblasts. It is well known that

fibroblasts are the main cellular components of connective tissues and they are responsible for the synthesis and upkeeping of the connective extracellular matrix. More particularly, HMGB1 acts in vitro as a
5 potent chemoattractant for fibroblasts and anti-RAGE antibodies block said effect.

Consequently, every kind of molecules having homology with HMGB1 can be used, as the entire full-length protein, for the preparation of pharmacological
10 agents which positively regulate, thus facilitate and/or induce cellular migration of fibroblasts. In the same way, every kind of molecules able to block the interaction between HMGB1 and its RAGE receptor (i.e. all the molecules belonging to the inhibitors group:
15 antibodies or antibodies fragments, four-way DNA; and all the molecules belonging to the HMG box-antagonists group: HMGB1 fragments, molecules containing the HMG box domain) can efficiently be used for the production of pharmacological agents in order to avoid, retard or
20 reduce connective tissues regeneration.

An additional aim of the present invention is the use of HMGB1, HMGB1 fragments corresponding to HMG box, HMG box domains of other proteins belonging to the HMG-box family and other proteins of the HMG-box family,
25 for the preparation of therapeutic agents which facilitate and/or induce fibroblasts migration and consequently positively regulate connective tissues regeneration.

Its is an integral part of the present invention
30 the use of all the molecules, antagonists and/or

inhibitors, which inhibit the interaction between HMGB1 and RAGE receptor, for the preparation of therapeutic agents which reduce, retard, and avoid connective tissues regeneration, as focused by the following
5 experiments.

Chemotaxis assay on fibroblasts

Chemotaxis assays were performed using well-known protocols (Degryse et al., 1999, Blood, 94:649-662).
10 Modified Boyden chambers were used with filters having 0.5 μ m pore size (Corning, Acton, MA) and treated with collagen I (100 μ g/ml in 0.5 M acetic acid) and fibronectin (10 μ g/ml) (Roche). Mouse embryonic fibroblasts were cultured following well-known
15 protocols (Calogero et al., 1999, Nat. Genet., 22:276-280) and after 24 hours of serum starvation, a sample of 20,000-40,000 cells was added to the upper well of Boyden chamber. E. Coli expressed recombinant-HMGB1 was diluted in the same serum-free medium and added to the
20 lower well.

Anti-RAGE antibodies (1000 ng/ml) (kind gift of Dr. A.M. Schimdt, Columbia University, NY) were added in both wells.

Overnight cell migration was allowed at 37°C, then
25 cells remaining on the upper surface of filters were scraped off and filters were fixed in methanol and stained in a solution of 10% crystal violet in 20% methanol. All experiments were performed at least twice in triplicate.

Results, as shown in figure 10 are the mean \pm SD of the number of cells counted in 10 high power fields per filter and expressed as fold over untreated control. To random cell migration (i.e. migration in absence of chemoattractant) was given the arbitrary value of 100%. Statistical analysis was performed using an ANOVA model for the evaluation of treatments with increasing doses of a reagent.

E. Coli expressed recombinant-HMGB1 stimulates fibroblasts migration in a concentration-dependent manner, starting at doses as low as 0,1 ng/ml and with a maximal response at 100 ng/ml, at higher doses (1000 ng/ml) the response is lower than the control. Anti-RAGE antibodies (1000 ng/ml) totally block the migratory response (right side of the graphic of figure 10) showing that this is specifically due to HMGB1.

ROLE OF HMGB1 IN THE REGULATION OF CONNECTIVE TISSUE REGENERATION.

The responsiveness of fibroblasts to HMGB1 points out to a possible role of HMGB1 during connective tissues remodelling occurring after damages due to traumatic events or surgery. Moreover, the fact that anti-RAGE antibodies block said response demonstrates that the interaction between HMGB1 and RAGE receptor on cellular surface is the basic event leading to fibroblast sensitiveness to HMGB1.

In conclusion:

- HMGB1 and/or HMGB1 fragments corresponding to HMG box, HMG box domains of other proteins belonging to

HMG-box family and other proteins of the HMG-box family are advantageously used for pharmacological preparations which positively regulate, i.e. facilitate and/or induce connective tissues regeneration.

- 5 - every kind of molecules able to inhibit the interaction between HMGB1 and RAGE, belonging to the antagonists group, (able to bond to RAGE receptor), and belonging to the inhibitors group, (i.e. able to bound the HMG box domain blocking HMGB1 bounding to RAGE
10 receptor) are advantageously used for pharmacological preparations which negatively regulate, i.e. block, retard or reduce connective tissues regeneration.

CLAIMS

- 1) The use of HMG box-binding molecules for the preparation of therapeutic agents for the treatment of vascular diseases.
- 2) The use of HMG box-binding molecules according to
5 claim 1 wherein said molecules belong to the group comprising antibodies or antibodies fragments, inhibitors and four-way DNA.
- 3) The use of antagonist molecules having sequence homology with HMG box and being able to bind the
10 functional HMG box binding domain of the receptor for the preparation of therapeutic agents for the treatment of vascular diseases.
- 4) The use of molecules according to one or more of the preceding claims wherein vascular diseases comprise
15 atherosclerosis and/or restenosis that occur during angioplasty.
- 5) The use of molecules according to one or more of the preceding claims wherein said molecules are released by catheters, surgical instruments or stents
20 for angioplasty.
- 6) The use of HMGB1 and/or HMGB1 fragments corresponding to HMG box, HMG box domains of other proteins belonging to HMG-box family and other proteins of the HMG-box family for the preparation of
25 therapeutic agents which facilitate and/or induce connective tissues regeneration.

7) The use of HMG box-binding molecules for the preparation of therapeutic agents which block, retard or reduce connective tissues regeneration.

8) The use of HMG box-binding molecules
5 according to claim 7 wherein said molecules belong to the group comprising antibodies or antibodies fragments, inhibitors and four-way DNA.

9) The use of antagonist molecules having
sequence homology with HMG box and being able to bind
10 the functional HMG box binding domain of the receptor for the preparation of therapeutic agents which block, retard or reduce connective tissues regeneration.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IT 02/00153

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/395 A61K31/7088 A61P9/00 A61P9/10 A61P17/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, PAJ, MEDLINE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 22138 A (UNIV COLUMBIA) 28 May 1998 (1998-05-28)	1-4,7-9
Y	pages 5-7; page 16, lines 11-19; page 19, lines 30-35	5
X	WO 97 39121 A (SCHERING AG) 23 October 1997 (1997-10-23)	1-4,7-9
Y	pages 2-3, 8-9, 26-28 and claims	5
X	WO 97 26913 A (UNIV COLUMBIA) 31 July 1997 (1997-07-31)	1-4,7-9
Y	claims 25-36	5
	-/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

13 June 2002

Date of mailing of the international search report

02/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

Renggli, J

Form PCT/ISA/210 (second sheet) (July 1992)

page 1 of 3

BNSDOCID: <WO_02074337A1_1>

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 02/00153

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document with indication where appropriate, of the relevant passages	Relevant to claim No
X	WO 00 47104 A (PICOWER INST MED RES) 17 August 2000 (2000-08-17)	1-3,7-9
Y	claims 1-3 and page 3-5	5,6
X	WO 97 39125 A (SCHERING AG) 23 October 1997 (1997-10-23)	3,4,9
Y	pages 2-3, 25-26 and claim 5	5
Y	WO 00 76573 A (SCIMED LIFE SYSTEMS INC) 21 December 2000 (2000-12-21)	5
	pages 8-9; claims 1-10	
Y	HERTEL I ET AL: "Decreased expression of the high-mobility group protein T160 by antisense RNA impairs the growth of mouse fibroblasts." BIOCHIMIE (PARIS), vol. 79, no. 12, December 1998 (1998-12), pages 717-723, XP002202049 ISSN: 0300-9084 the whole document	6
Y	YAMAZAKI FUMINORI ET AL: "Repression of cell cycle progression by antisense HMG2 RNA." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 210, no. 3, 1995, pages 1045-1051, XP002202050 ISSN: 0006-291X the whole document	6
A	STROS MICHAL ET AL: "A role of basic residues and the putative intercalating phenylalanine of the HMG-1 box B in DNA supercoiling and binding to four-way DNA junctions." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 46, 2000, pages 35699-35707, XP002202051 ISSN: 0021-9258 the whole document	1,2,7,8

-/-

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

page 2 of 3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 02/00153

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>DEGRYSE BERNARD ET AL: "The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells."</p> <p>JOURNAL OF CELL BIOLOGY, vol. 152, no. 6, 19 March 2001 (2001-03-19), pages 1197-1206, XP002202052 ISSN: 0021-9525 the whole document</p>	1-9

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IT 02/00153

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9822138	A	28-05-1998	AU 745241 B2	14-03-2002
			AU 5263998 A	10-06-1998
			EP 0946196 A1	06-10-1999
			JP 2001504493 T	03-04-2001
			WO 9822138 A1	28-05-1998
WO 9739121	A	23-10-1997	AU 2696097 A	07-11-1997
			WO 9739121 A1	23-10-1997
			ZA 9703242 A	05-08-1998
WO 9726913	A	31-07-1997	AU 1832797 A	20-08-1997
			WO 9726913 A1	31-07-1997
WO 0047104	A	17-08-2000	US 6303321 B1	16-10-2001
			AU 3698300 A	29-08-2000
			EP 1165110 A2	02-01-2002
			WO 0047104 A2	17-08-2000
WO 9739125	A	23-10-1997	US 5864018 A	26-01-1999
			AU 2385597 A	07-11-1997
			WO 9739125 A1	23-10-1997
			ZA 9703247 A	02-12-1997
WO 0076573	A	21-12-2000	US 6398808 B1	04-06-2002
			AU 5868100 A	02-01-2001
			EP 1189656 A1	27-03-2002
			WO 0076573 A1	21-12-2000

Form PCT/ISA/210 (patent family annex) (July 1992)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 02/074337 A1

(51) International Patent Classification¹: **A61K 39/395**,
31/7088, A61P 9/00, 9/10, 17/02

(74) Agent: **SARPI, Maurizio**; Studio Ferrario, Via Collina,
36, I-00187 Roma (IT).

(21) International Application Number: **PCI/IT02/00153**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LI, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: **12 March 2002 (12 03 2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
MI2001A000562 **16 March 2001 (16 03 2001)** **II**

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **BIO3 RESEARCH S.R.L.** [IT/IT]; Largo Rosolino Pilo, 39/A, I-95126 Catania (IT)

Published:
— *with international search report*

(71) Applicant and
(72) Inventor: **BIANCHI, Marco, E.** [IT/IT]; Viale Abruzzi, 4/C, I-20068 Peschiera Borromeo (IT).

(48) Date of publication of this corrected version:
28 August 2003

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): **BONALDI, Tiziana** [IT/IT]; Via Griffini, 5, I-26013 Crema (IT). **SCAFFIDI, Paola** [IT/IT]; Via Asilo, 82, I-20010 Cornaredo (IT). **MUELLER, Susanne** [DE/IT]; Via Vittorio Emanuele, 15, I-20052 Monza (IT). **DEGRYSE, Bernard** [FR/FR]; Terrasse du Clos Malaga 11, F-13340 Rognac (FR)

(15) Information about Correction:
see PCT Gazette No 35/2003 of 28 August 2003, Section II
For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/074337 A1

(54) Title: **HMGB1 PROTEIN INHIBITORS AND/OR ANTAGONISTS FOR THE TREATMENT OF VASCULAR DISEASES**

(57) Abstract: The use of HMG box-binding molecules and molecules having sequence homology with HMG box for the preparation of therapeutic agents for the treatment of vascular diseases is described.